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Summary Merseyside and Cheshire Cancer Registry (MCCR) data quality was assessed by applying literature-based measures to 27 942
cases diagnosed in 1990 and 1991. Registrations after death (n = 8535) were also audited (n = 917) to estimate death certificate only (DCO)
case accuracy and the proportion of registrations notified by death certificate (DC). Ascertainment appeared to be high from the
registration/mortality ratio for lung [1.01:1] and to be low from capture-recapture estimates (59.4%), varying significantly with site from
oesophagus [92.2% (95% Cl 88.5-95.9)] to breast [47.5 (95%CI 41.8-53.2)]. The estimated DC-dependent proportion was 20% (5601 out of
27 942) with successful traceback in 3533 out of 5601 (63.1%) cases. DCO flagging (2497 out of 27 942, 8.9%) overestimated true DCO
cases (2068 out of 27 942, 7.4%). The proportion of cases of unknown primary site was low (1.5%), varying significantly with age [0-4.2%,
(95% Cl 2.5-5.9)] and district [0.8% (95% Cl 0.3-1.3) to 2.2% (95% Cl 1.8-2.6)]. The median diagnosis to registration interval appeared to be
good (10 weeks), varying significantly with site (P < 0.0001), age (P < 0.0001) and district (P < 0.0001). The proportion with a verified
diagnosis was 77.3%, varying significantly with site [lung 55.2% (95% Cl 53.7-56.7) to cervix 96.9% (95% Cl 96.3-97.5)], age [45.2% (95%
Cl 40.9-49.5) to 97.5% (95% Cl 96.4-98.6)] and district [71.8% (95% Cl 69.9-73.8) to 82.5% (95% Cl 80.7-84.3)]. The DCO percentages
varied similarly by site [non-melanoma skin 0.4% (95% Cl 0.2-0.6) to lung 22.6% Cl (95% 19.9-25.3)], age [0.7(95% Cl 0.1-1.4) to 23.0 (95%
Cl 19.4-26.6)] and district [6.9% (95% Cl 5.7-8.1) to 13.9% (95% Cl 12.9-15.0)]. MCCR dataqualityvaried with age, site and district -inviting
action - and apparently compares favourably with elsewhere, although deficiencies in published data hampered definitive assessment.
Putting quality assurance into practice identified shortcomings in the scope, definition and application of existing measures, and absent
standards impeded interpretation. Cancer registry quality assurance should henceforward be within an explicit framework of agreed and
standardized measures.
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Population-based cancer registration aims to register every patient
diagnosed with cancer within a defined geographical area
(Freedman, 1978) to inform health policy makers, service
purchasers and providers, and researchers. In England and Wales,
12 regional registries form the largest population-based cancer
register in the world (Swerdlow, 1986). Started in 1944,
Merseyside and Cheshire Cancer Registry (MCCR - previously
Mersey Regional Cancer Registry) registers about 13 000 new
cancers annually from apopulation of2.4 million (Youngson et al,
1992), receiving initial information from pathology laboratories,
death certificates (DCs) mentioning cancer and hospital informa-
tion systems. Further information about the individual, the tumour
and its clinical management, and outcome, is obtained from hospi-
tals, general practitioners, nursing homes, private hospitals,
hospices and the Office of National Statistics (ONS - previously
the Office of Population Censuses and Surveys, OPCS). MCCR
routinely supplies an agreed Cancer Minimum Data Set (NHS
Management Executive, 1992) to ONS and collects additional
data, especially about treatment, for local use.
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The importance of quality assurance is emphasized internation-
ally in 'Cancer Incidence in Five Continents' (Parkin and Muir,
1992) and, intheUK, by its inclusion inregional corporatecontracts
for cancerregistration (NHS ManagementExecutive, 1996).
Four attributes of registry data quality are described.
Ascertainment is 'the degree to which reportable incident cases ...
are actually recorded in theregistry' (Robles et al, 1988). It is vari-
ously termed 'accuracy', 'completeness', 'completeness of regis-
tration' and 'completeness of ascertainment' by authors. The use
of 'ascertainment' alone avoids confusion with completeness of
detail and is consistent with the English meaning (Collins Concise
English Dictionary, 1982). Completeness (of detail) describes the
extent to which all appropriate data items have been recorded
(Skeet, 1991). Timeliness describes the currency of registry data.
Validity is 'the proportion of cases recorded with a given charac-
teristic (sex, age, diagnosis) which truly has this attribute' (Parkin
and Muir, 1992).
MCCR ascertainment has previously been reported as 88.7% for
childhood cancers compared with 91.8% in England and Wales
(Hawkins and Swerdlow, 1992). Incidence to mortality ratios for
lung cancer were 1.12 and 1.11 for men and women, respectively, in
1989, compared with equivalent ratios for England and Wales of
1.06 and 1.07 (OPCS, 1994). These measures, although limited,
imply ascertainment worse than the national average in MCCR.
Similarly, MCCRranks seventh outofnine UKregistries submitting
667668 DJ Seddon and EMI Williams
datainternationally for the overall proportion histologically verified:
66% men and 71% women compared with equivalent figures from
the Oxford Regional Registry of 76% and 80% (Parkin and Muir,
1992), implying suboptimal validity. The dearth of information
about the quality ofMCCR data, and the implication from the small
amountpublished thatimprovement is needed, prompted the aims of
this study, i.e. to identify data quality measures from the literature,
apply them to MCCR data and make recommendations for quality
assurance extendable to otherregistries.
MATERIALS AND METHODS
Published papers, reference volumes, OPCS publications and
reports from UK and overseas registries were searched to identify
measures of cancer registry data quality. Measures of ascertain-
ment, completeness, timeliness and validity were selected
according to their reproducibility (adequately described with few
assumptions, clear definitions and simple calculations), practica-
bility (relevant information collected by MCCR) and potential
comparability with data from other registries.
Data items, e.g. age at diagnosis, cancer site coded to three
digits in ICD-O [International Classification of Diseases for
Oncology (Version 1)] and district ofresidence at diagnosis, were
selected according to their association with previously identified
measures on all registered cases diagnosed in 1990 and 1991 to
form the study database. The measures were then applied to the
study database and analysed by district of residence, age at
diagnosis and cancer site.
For measures requiring information about notification source,
which was not computerized in MCCR, the paper records ofcases
registered after death were audited separately to determine those
cases that were uniquely dependent on the DC for notification and
the accuracy of death certificate only (DCO) cases identification.
For cases registered from a DC, by local convention, date ofdeath
is also entered on to the computer as date of diagnosis until more
information becomes available, thereby flagging DCO cases. Four
random samples of registrations after death were selected,
according to the presence or absence of the DCO flag and the
length of the death to registration interval. Sample sizes were
calculated for a population survey with a single parameter having
an estimated frequency of 50%. Sample paper records were
searched manually for independent source documents, forming an
audit database of key identifying variables and information
about notification source. Representativeness was confirmed by
comparing the frequencies of five variables (sex, age group, site,
year of diagnosis and district of residence) between each sample
and the study database. Death certificate-dependent (DCD) regis-
trations were defined as those containing a death certificate as the
only notifying paper document. Records containing notifications
from other sources (e.g. pathology), even iffirst notified by DC,
were regarded as independently notified. DCDs were reclassified
as DC-plus registrations when registry enquiry (traceback) yielded
additional information, and DCO registrations when traceback
was unsuccessful.
When possible, results are presented with confidence limits,
calculated using standard formulae (Gardner and Altman, 1992).
Statistical significance was assessed using the Kruskal-Wallis test
foranalysis ofvariance and Spearman's rankcorrelationcoefficient.
RESULTS
Ten measures were identified from the literature (Table 1), all
lacking explicit standards. The study database contained 27 942
primary cancers diagnosed in 1990 and 1991, of which 8535
Table 1 Measures of quality assurance
Quality Measure Source Comment
assurance area
Ascertainment Registration - mortality ratio Balarajan and Scott (1983)
Swerdlow (1986) See appendix for worked
Capture-recapture Robles et al (1988) example
Death certificate - dependent proportion (DCD%) Freedman (1978) Cases uniquely notified by
Goldberg et al (1980) death certificate
Skeet (1991)
Death certificate - notified proportion (DCN%) Benn et al (1982) Cases first notified by
Parkin et al (1994) death certificate
Completeness Primary site-unknown proportion Parkin and Muir (1992)
Proportion of cases with missing information Parkin and Muir (1992) As missing date of birth and sex
Timeliness Diagnosis to registration interval Thames Cancer Registry (1992) As median and 75th percentile
Validity Proportion of cases with a verified diagnosis Parkin and Muir (1992) As sum of histopathological proof,
cytological proof and other
'special tests'; e.g. blood films and
special imaging
Death certificate-only proportion (DCO%)a Parkin and Muir (1992) Approximated by the DCO
Black et al (1993) flagged proportion
Parkin and Muir (1992)
Consistency checks Skeet (1991) e.g. Between sex and site,
dates of diagnosis and
registration
aDCO% is also a measure of completeness.
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Table 2 Cases registered after death: weighted estimates in the study population (n = 8535) based on audited records (n = 917)
Category DCO flagged No DCO flag Totals
Death registration interval Death registration interval
< 6 weeks .6 weeks < 6 weeks >6 weeks
n (%) n (%) n (%) n (%) n (%)
Population 2333 (100) 164 (100) 5530 (100) 508 (100) 8535 (100)
(Sample selected) (320) (123) (357) (217) (1017)
(Sample audited) (281) (105) (335) (196) (917)
Death certificate independent 257 (11.0) 36 (22.0) 2361 (42.7) 280 (55.1) 2934 (34.4)
Death certificate plus 125 (5.4) 11 (6.7) 3169 (57.3) 228 (44.9) 3533 (41.4)
Death certificate only 1951 (83.6) 117 (71.3) - - - 2068 (24.2)
Death certificate dependent 2076 (89.0) 128 (78.0) 3169 (57.3) 228 (44.9) 5601 (65.6)
Table 3 Registration to mortality (R/M) ratios by district in Mersey NHS
region 1990 and 1991 (both sexes) for cancers of the stomach (ICDa 151),
trachea, bronchus and lung (ICD 162)
District Site
Registered cases R/M ratio
Stomach Lung Stomach Lung
1 53 219 1.39 1.01
2 95 325 1.46 1.03
3 298 1223 1.32 1.19
4 177 622 1.30 1.14
5 176 684 1.26 1.05
6 76 250 1.33 1.04
7 117 321 1.30 1.01
8 56 227 1.33 1.06
9 83 260 1.15 1.17
10 86 267 1.26 1.19
Mersey region 1217 4398 1.30 1.11
Source: Mersey Regional Cancer Registry data 1990-91 and OPCS series
DH5 'Mortality in England and Wales by area, 1990 and 1991'. alCD,
International Classification of Diseases.
(32.2%) were registered after death. The audit samples comprised
1017 out of8535 (11.9%) cases, ofwhich 917 out of 1017 (90.2%)
were successfully traced, forming the audit database. The distribu-
tion ofattributes (age, sex, site ofcancer, district ofresidence, year
of diagnosis) in the audit samples was comparable with those in
the four parent populations. Table 2 shows the weighted estimates
for the study database derived from the audit.
Ascertainment
Overall, Mersey registration to mortality (R/M) ratios were 1.30:1
and 1.1:1 for stomach (ICD-O 151) and lung cancer (ICD-O 162)
respectively. District ratios for lung and stomach cancers within
Mersey region (Table 3), although variable, exceeded unity; ratios
for stomach cancer were appropriately and consistently higher
than those for lung, reflecting better survival.
Table 4 shows considerable variation between sites for
capture-recapture estimates. The 'all sources' estimate of
ascertainment (59.4% overall) was greater than the 'two source'
estimate (52.5% overall), because cases ascertained from other
sources (e.g. hospital information systems) were included.
Ascertainment appeared low for sites like female breast in which
overlap between sources was small, i.e. when survival is longer
and hence there are fewer DC notifications. When overlap was
greater, e.g. for lung, ascertainment appeared to be higher. For
sites with effectively a single source (e.g. testis - pathology only),
the method failed as there was no 'recapture'.
From the audit, the DCD% (cases uniquely notified by DC) was
65.6% (5601 out of 8535) of registrations after death and 20%
(5601 out of27 942) overall, comprising 24.2% (2068) DCO cases
and 41.4% (3533) DC-plus cases (Table 2). The DC-notified
proportion (DCN%) (casesfirst notified by DC) was an estimated
96.7% (8255 out of 8535) of cases registered after death and
29.5% (8255 out of 27 942) overall, comprising 5601 DCD cases,
293 DC-independent cases (DCO flagged and thus triggered by a
DC) and 2361 unflagged cases registered within 6 weeks of death
(likely to have been triggered by a DC). An estimated 2934
(34.4%) registrations after death were DC independent.
Completeness
The proportion of cases with an unknown primary site varied
significantly among districts (Table 5) and with age, being low
initially in children and young adults but increasing thereafter
(Table 6). Date ofbirth and sex were missing in 13 and two records
(< 0.01%) respectively.
Timeliness
The median diagnosis to registration interval for Mersey region
was 10 weeks. An exceptional interval of 24 weeks in district 7
compared with a range from 8 to 12 weeks in other districts
(Kruskall-Wallis P < 0.0001) (Table 5). The interval decreased
with increasing age (Spearman rank P < 0.0001) (Table 6) and
varied significantly with site from 8 weeks (oesophagus) to 16
weeks (brain) (Table 7). The median and 75th percentile values
varied similarly by age, site and district.
Validity
Among districts, the proportion with a verified diagnosis varied
significantly from 71.8% to 82.5%, with a regional average
of 77.3% (Table 5). Verification varied significantly with age,
British Journal ofCancer(1997) 76(5), 667-674 0 Cancer Research Campaign 1997670 DJ Seddon andEMI Williams
Table 4 Estimated ascertainment by selected site using capture-recapture methods, Mersey Regional Cancer Registry 1990-91
Percentage ascertainment (95% confidence limits)
Site (ICD-O) Number of registered cases Two sourceb All sourcesc
Oesophagus (150) 623 89.1 (85.5-92.6) 92.2 (88.5-95.9)
Stomach (151) 1217 84.2 (81.2-87.2) 86.3 (83.2-89.4)
Colon (153) 1790 62.3 (58.6-66.1) 65.5 (61.6-69.5)
Rectum (154) 1070 70.5 (65.9-75.0) 75.9 (71.0-80.8)
Larynx (161) 228 74.3 (62.5-86.1) 91.1 (76.6-100)
Trachea, bronchus and lung (162) 4398 81.2 (79.1-83.3) 85.7 (83.4-87.9)
Haematopoietic tissue (169) 921 50.9 (43.7-58.1) 86.2 (74.0-98.4)
Non-melanomatous skin (173) 4627 62.1 (56.0-68.3) 70.8 (63.8-77.8)
Female breast (174) 2749 36.4 (32.0-40.8) 47.5 (41.8-53.2)
Uterine cervix (180) 2783 46.8 (38.6-55.1) 58.7 (48.4-69.1)
Uterine body (182) 355 55.6 (44.2-66.9) 69.7 (55.5-84.0)
Ovary (183) 460 70.5 (63.3-77.7) 82.9 (74.5-91.4)
Prostate (185) 1122 62.7 (57.7-67.8) 69.6 (64.0-75.2)
Testis (186) 117 81.1 (30.7-100) 100 (52.1-100)
Bladder (188) 1160 64.9 (59.8-70.1) 73.1 (67.3-79.0)
Brain (191) 399 70.9 (62.8-79.0) 77.5 (68.6-86.4)
Unknown primary (199) 406 69.6 (37.0-100) 71.9 (38.2-100)
All sites (140-208, excluding 172) 27 942 52.5 (51.4-53.5) 59.4 (58.2-60.6)
alnternational Classification of Diseases for Oncology - Version 1. bTwo-source method: observed cases notified from pathology and death certificate
notifications. cAll-source method: observed cases as for two-source method plus clinically notified cases. In both methods, expected cases are calculated using
the capture-recapture method (Appendix).
Table 5 Quality indicators in Mersey Regional Cancer Registry 1990-91: district of residence
District Cases Verification of diagnosisa DCO flagb Primary site unknown Diagnosis to registration interval (weeks)
% (95% CL) % (95% CL) % (95% CL) Medianc (95%CL) 75th percentile
1 1746 82.5 (80.7-84.3) 6.9 (5.7-8.1) 1.0 (0.5-1.5) 8 (7-8) 14
2 1973 76.8 (74.9-78.7) 10.9 (9.5-12.3) 1.9 (1.3-2.5) 12 (11-12) 20
3 6592 80.0 (79.0-81.0) 8.3 (7.7-9.0) 1.2 (0.9-1.5) 10 (10-10) 17
4 3961 78.3 (77.0-79.6) 9.2 (8.3-10.1) 1.3 (1.0-1.7) 10 (9-10) 15
5 4326 73.2 (71.9-74.5) 13.9 (12.9-15.0) 2.2 (1.8-2.6) 9 (8-9) 15
6 2010 80.1 (78.4-81.9) 7.2 (6.0-8.3) 1.0 (0.6-1.5) 8 (7-8) 14
7 2052 71.8 (69.9-73.8) 6.2 (5.2-7.3) 2.0 (1.4-2.6) 24 (22-25) 56
8 1463 78.0 (75.9-80.1) 7.0 (5.7-8.4) 0.8 (0.3-1.3) 10 (9-10) 16
9 1972 77.6 (75.8-79.4) 7.2 (6.0-8.3) 1.1 (0.6-1.6) 9 (8-9) 18
10 1847 72.6 (70.6-74.6) 6.9 (5.8-8.1) 1.4 (0.9-1.9) 10 (9-10) 17
All districts 27942 77.3 (76.8-77.8) 8.9 (8.6-9.3) 1.5 (1.4-1.6) 10 (10-10) 17
aVerification includes pathological and cytological proof as well as proof by 'special test'. bThe Registry DCO flag overestimated 'true' DCO registration - see
text. cKruskal-Wallis X2 = 1340 (9 d.f.), P < 0.0001. 95% CL, 95% confidence limits.
increasing to aplateau between ages 25 and 34 years andthereafter
decreasing (Table 6). Table 7 shows significant variation in verifi-
cation by site, from 55.2% (lung) to 96.9% (cervix).
There were an estimated 2497 out of 8535 (29.3%) DCO-flagged
cases and 2068 out of 8535 (24.2%) true DCO cases based on the
audited sample,giving overall DCO proportions of 8.9% (2497 out
of 27 942) and 7.4% (2068 out of 27 942), respectively, 8 months
after the end ofthe studyperiod (Table 2). The DCOflag had aposi-
tive predictive value estimate of 83% (2068 out of 2497), thereby
acting as a reasonable proxy for true DCO cases, and varied with
death to registration interval from 71% (117 out of 164) under 6
weeks to 84% (1951 out of2333) at or over 6 weeks. The 429 DCO
flag errors (1.5% overall) arose through the misclassification of 293
(68%) DC-independent cases and 136 (32%) DC-plus cases. There
were significant differences between districts for DCO-flagged
cases, with a twofold difference between the extreme values (Table
5). The DCO-flagged proportion varied significantly with age,
initially decreasing in children and young adults, thereafter
increasing (Table6), and variedsignificantly with site, fromless than
2.5% in larynx, cervix and skin to 22.6% for haematopoietic malig-
nancies and 56.4% when theprimary site is unknown (Table 7).
The sumofverified and DCO flagged cases appropriately did not
exceed 100% for any district, age group or site. There were no
uniquely female cancers recorded in men orvice versa. In 530 cases
(1.9%) recorded, date ofregistrationpreceded the date ofdiagnosis.
DISCUSSION
While there is agreement about the value of quality assurance in
cancerregistries, clearly this must be standardized and universally
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Table 6 Quality indicators in Mersey Regional Cancer Registry 1990-91: age group
Age group Cases Verification of diagnosisa DCO flagb Primary site unknown Diagnosis to registration interval (weeks)
(years)
% (95% CL) % (95% CL) % (95%CL) Medianc (95% CL) 75th percentile
0-4 50 74.0 (61.2-86.2) 10.0 (1.7-18.3) 2.0 (0.0-5.9) 27 (17-30) 40
5-9 20 80.0 (62.5-97.5) 5.0 (0.0-14.6) 0 28 (16-35) 42
10-14 28 89.3 (77.8-100) 3.6 (0.0-10.4) 0 25 (17-34) 42
15-19 90 93.3 (88.2-98.5) 1.1 (0.0-3.3) 0 20 (15-18) 34
20-24 396 96.7 (94.9-98.5) 1.3 (0.2-2.4) 0.3 (0.0-0.8) 12 (11-13) 25
25-29 667 97.5 (96.3-98.6) 0.7 (0.1-1.4) 0 13 (12-13) 23
30-34 839 97.5 (96.4-98.6) 1.4 (0.6-2.2) 0.2 (0.0-0.6) 13 (12-13) 23
35-39 709 94.5 (92.8-96.2) 1.0 (0.3-1.7) 0.4 (0.0-0.9) 12 (11-13) 20
40-44 874 94.2 (92.6-95.7) 1.8 (1.0-2.7) 0.3 (0.0-0.7) 13 (12-13) 23
45-49 1080 91.9 (90.3-93.6) 2.0 (1.2-2.9) 0.3 (0.0-0.6) 11 (11-12) 20
50-54 1571 87.7 (86.1-89.3) 3.9 (3.0-4.9) 1.2 (0.7-1.8) 10 (9-10) 17
55-59 2061 84.4 (82.9-85.9) 5.4 (4.4-6.4) 0.8 (0.4-1.2) 10 (9-10) 17
60-64 3195 82.0 (80.7-83.3) 6.4 (5.5-7.2) 1.2 (0.8-1.6) 10 (9-10) 16
65-69 3964 76.8 (75.5-78.1) 9.0 (8.1-9.9) 1.3 (1.0-1.7) 9 (8-9) 17
70-74 3793 73.0 (71.6-74.4) 10.2 (9.2-11.1) 1.3 (1.0-1.7) 9 (8-9) 16
75-79 3893 70.7 (69.3-72.1) 11.6 (10.6-12.6) 1.8 (1.4-2.2) 9 (8-9) 17
80-84 2786 64.1 (62.3-65.9) 16.2 (14.8-17.6) 2.9 (2.3-3.5) 8 (7-8) 15
85-89 1391 55.1 (52.5-57.8) 20.1 (18.0-22.2) 2.9 (2.1-3.8) 8 (7-8) 16
90+ 522 45.2 (40.9-49.5) 23.0 (19.4-26.6) 4.2 (2.5-5.9) 7 (6-8) 15
All ages 27 942 77.3 (76.8-77.8) 8.9 (8.6-9.3) 1.5 (1.3-1.6) 10 (10-10) 17
aVerification includes pathological and cytological proof as well as proof by 'special test'. bThe Registry DCO flag overestimates 'true' DCO registrations - see
text. cSpearman correlation coefficient = 0.1375, P< 0.0001. 95% CL, 95% confidence limits.
Table 7 Quality indicators in Mersey Regional Cancer Registry 1990-91: site
Site (ICD-O) Cases Verification of diagnosisa DCO-flagb Diagnosis to registration interval (weeks)
% (95% CL) % (95% CL) Medianc (95% CL) 75th percentile
Lip, mouth and pharynx (140-149) 469 90.6 (87.0-93.2) 3.6 (1.9-5.3) 11 (10-12) 23
Oesophagus (150) 623 71.7 (68.2-75.2) 13.8 (11.1-16.5) 8 (7-9) 14
Stomach (151) 1217 70.9 (68.3-73.5) 13.1 (11.2-15.0) 8 (7-8) 14
Colon (153) 1790 75.1 (73.1-77.1) 11.4 (9.9-12.9) 9 (8-9) 16
Rectum (154) 1070 84.8 (82.7-87.0) 6.9 (5.4-8.4) 9 (8-9) 16
Larynx (161) 228 90.8 (87.1-94.6) 2.2 (0.29-4.1) 9 (7-9) 16
Trachea, bronchus and lung (162) 4398 55.2 (53.7-56.7) 15.6 14.6-16.7 8 (7-8) 15
Haematopoietic (169) 921 67.4 (64.4-70.4) 22.6 (19.9-25.3) 10 (8-11) 25
Skin (non-melanoma) (173) 4627 92.9 (92.2-93.6) 0.4 (0.2-0.6) 10 (10-10) 16
Female breast (174) 2749 85.2 (83.9-86.5) 5.3 (4.5-6.1) 11 (10-11) 18
Cervix uteri (180 ) 2783 96.9 (96.3-97.5) 0.9 (0.5-1.2) 13 (12-13) 24
Body uterus (182) 355 90.7 (87.7-93.7) 5.6 (3.2-8.0) 10 (9-11) 20
Ovary (183) 460 79.1 (75.4-82.8) 8.3 (5.7-10.8) 10 (9-12) 21
Prostate (185) 1122 83.6 (81.4-85.8) 7.0 (5.5-8.4) 10 (10-11) 17
Testis (186) 117 95.7 (92.0-99.4) 2.6 (0.0-5.4) 11 (8-11) 23
Bladder (188) 1160 90.0 (88.3-91.7) 4.9 (3.7-6.2) 10 (9-10) 16
Brain (191) 399 65.7 (61.0-70.4) 14.0 (10.6-18.1) 16 (14-18) 26
Unknown primary (199) 406 28.1 (23.7-32.5) 56.4 (51.6-61.2) 4 (3-4) 9
Other sites (within 140-208) 3048 63.6 (61.5-64.9) 12.7 (12.1-13.3) 9 (8-9) 30
All cancers (140-208) 27 942 77.3 (76.8-77.8) 8.9 (8.6-9.3) 10 (10-10) 17
aVerification includes pathological and cytological proof as well as proof by 'special test' (11% of haematopoietic and 2.5% of brain cancers had proof by 'special
test' - for other sites such proofs were negligible). bThe Registry DCO flag overestimates 'true' DCO registrations - see text. cKruskal-Wallis one-way analysis
of variance of ranks: X2 = 1111 (17 d.f.), P < 0.0001. 95% CL, 95% confidence limits.
applied to allow meaningful comparisons, interpreted in the to bring quality assurance into practice. Although the assessment
context of registration practice and sufficiently disaggregated to ofoverall quality in MCCR was constrainedby the lack ofcompa-
facilitate improvement. This first attempt to apply published rable data fromelsewhere, nevertheless significant variations were
measures comprehensively at the local level should be viewed as exposed, demanding clear action and inviting further explanation.
complementary to larger, infrequent, endeavours such as Cancer A local baseline has now been established against which to set
Incidence in Five Continents (Parkin and Muir 1992) in attempting standards, negotiate improvement and monitorpractice.
British Joumal ofCancer(1997) 76(5), 667-674 0CancerResearch Campaign 1997672 DJ Seddon and EMI Williams
Ascertainment
Overall MCCR R/M ratios for lung cancer remain consistent
(1.11:1 in 1990/1 compared with 1.12:1 and 1.11:1 for men and
women, respectively, in 1989), showing little improvement.
Comparative published data on district RIM ratios are few but
shows similar variation (Centre for Cancer Epidemiology, 1992).
Regional comparisons of R/M ratios although published annually
(OPCS, 1994) are robust when deaths are expected to equal
incidence and are difficult to interpret otherwise. For rapidly fatal
cancers, R/M ratios under one imply underascertainment and
values over one suggest duplication whereas, for other cancers,
R/M ratios of 1:1 may signal underascertainment. The R/M ratio
incorporates DC diagnostic uncertainty and for most sites lacks an
explicit optimum. Furthermore, using the R/M ratio for rapidly
fatal cancers to reflect overall ascertainment wrongly assumes that
their ascertainment is typical.
There is little UK literature using capture-recapture to estimate
cancer registry ascertainment. Ascertainment in MCCR 59%
apparently compares unfavourably with results from Ontario
59-95% (Robles et al, 1988). However, Robles' study was reported
6 years after the incident year (compared with 8 months in our
study), leading to more observed cases and more overlap between
sources (e.g. death certificate and pathology), particularly affecting
sites with longer survival such as breast and cervical cancer. Also,
the accurate identification of source in Robles' study allowed three
sources to be used (compared with two in our study), thereby
strengthening the method. The method is most robust when capture
and recapture give similarly sized groups, are clearly independent
and have considerable overlap. Capture-recapture fails when there
is a single source (e.g. for testicular cancer, which has excellent
survival) and overestimates ascertainment when sources are mutu-
ally dependent (e.g. between death certificate and post-mortem
data). Capture-recapture results here may thus illustrate the
method's shortcomings as much as they measure local ascertain-
ment. However, the method deserves further testing (perhaps
against independent clinical case registers) and could be refined for
cancer registry use by specifying the time interval after the incident
year, using multiple sources, considering sites individually and
adjusting for survival time.
Both R/M ratios and capture-recapture depend on multiple
sources of information and, although probably less accurate, are
easier to applyroutinely than more resource intensive comparisons
with clinical case registers (which tend to be site specific and have
limited population coverage) or data reabstraction methods.
The DCD% estimated from audited registrations after death was
preferred to the more familiar DCN%, which refers to casesfirst
notified by DC. The DCD%, in identifying uniquely DC notified
cases, is the better measure of ascertainment as 'accidents of
timing', occurring when DC information apparently arrives in the
Registry first, are eliminated. In MCCR, death certificates are
processed before information from other sources to maximize the
likelihood of successful traceback. Thus, rapidly fatal cancers in
particular may be notified first, but not uniquely, by DC, and data
processing backlogs, common to many registries, make ascertain-
ment measured by DCN% appear worse by affecting timeliness.
Overall DCD% and DCN% were estimated as 20.0% and 29.5%,
respectively, illustrating the potential for distortion. Routine
description of the DCD% is impossible, however, without infor-
mation about notification source. There are no comparable data
from other registries.
Approximately 10% of records selected for audit were 'not in
file' mainly through removal for research and (paradoxically) veri-
fication purposes. Filing has since been reorganized!
Completeness
The overall proportion with primary site unknown (1.5%) appears
to have improved compared with levels of 6.23% and 6.95% for
men and women respectively (Parkin and Muir, 1992), although
the best district value of 0.8% indicates that further local improve-
ment is possible. Improvement may reflect extensions in the range
and application of diagnostic techniques. Although there are no
comparable published reports about other missing key informa-
tion, the overall proportions in MCCR appear acceptably low.
The DCO% measures completeness, as key data items such as
date of diagnosis are missing, and validity (see on) mainly by
affecting diagnostic accuracy. The effect of these deficiencies on
incidence and survival analyses clearly depends upon the
magnitude of the DCO% and the degree to which DCO cases
are atypical. DCO registrations represent ascertainment failures
comprising genuine diagnoses after death and cases unreported in
life for which traceback has either been unsuccessful or has not
been attempted. In MCCR, DCO registrations (7.4%) were overes-
timated by the DCO flag (8.9%). Misclassification arose through
clerical failure to reset date ofdiagnosis (from date ofdeath) when
additional information was found, with clear implications for
training. DC-independent cases, incorrectly DCO flagged, arose
through dataprocessing backlogs during recomputerization, which
differentially affected sources other than death certificates. Similar
mechanisms probably account for the variation in the positive
predictive value of the DCO flag with death to registration
interval. In MCCR, variations in the DCO-flagged proportion by
site, age and district are likely to be a reasonable reflection of true
DCO% variation (positive predictive value 83%) and raise issues
for exploration with data providers.
Traceback was successful in 3533 out of 5601 (63.1%) DCD
cases, thereby improving validity and completeness, as otherwise
all DCD registrations would eventually be classified DCO. The
DC-plus% estimated here provides a new marker of ante-mortem
reporting failure. Less biased than DCO registrations, most DC-
plus cases are randomly 'missed pathology', causing delays rather
than failures in record completion, and may be indistinguishable in
content from registrations completed chronologically. There are
no comparable figures from other registries.
Timeliness
MCCR registration timeliness compares favourably with else-
where, with median diagnosis to registration intervals of 10 weeks
and 24 weeks for MCCR and South Thames respectively (Thames
Cancer Registry, 1995). In MCCR, statistically significant varia-
tions in the diagnosis to registration interval are highlighted by
site, district and age group. Explanations for delays include
complex childhood cancer records not being available to registra-
tion clerks, routine failure to notify histological diagnoses,
especially in district 7, and a greater proportion of 'faster' DC
notifications among older people and in some districts. The impli-
cations of these findings need to be explored with individual
providers if registration is to be improved. Commonly registered
more promptly that registrations via pathology, DCO cases should
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ideally be excluded from calculations oftimeliness, but they were
known only for the audited records, precluding their exclusion
here. Comparisons with otherregistries were limitedby the lack of
published data, although South Thames data also showed some
variation with site and district (Thames Cancer Registry, 1995).
The diagnosis to registration interval (expressed as median and
75th percentile) uses routinely available data from the Cancer
Minimum Data Set (NHS Management Executive, 1992) and
depends upon ascertainment and the elapsed time from the inci-
dent year. This time could be standardized to allow more mean-
ingful comparison between registries, thereby better reflecting the
process ofregistration.
Validity
Variations in the proportion ofhistologically verified diagnoses by
site (Centre for Cancer Epidemiology, 1992; Parkin and Muir,
1992) and age (Parkin and Muir, 1992) are confirmed, and district
variations are reported that illuminate cause. The histologically
verified proportion assesses the validity of registration data
(Centre for Cancer Epidemiology, 1992; Parkin and Muir, 1992;
Black et al, 1993) but again lacks clear definition, hampering
comparisons. The inclusion or exclusion of haematology and
cytology reports alters the proportion of records defined as
'histologically' verified. This problems applies especially to
haematopoietic and cervical cancers, in which treatment decisions
are routinely based on blood and cytology reports. This may partly
explain ourfinding ofapparently lowerverification in children and
young adults. An alteration ofterminology is suggested. Instead of
using the term 'histological verification', verification of diagnosis
could be given three broad levels: microscopic, specific biochem-
ical and imaging techniques; and clinical. Each level requires
exclusive definition to include all diagnostic techniques and
should keep pace with technological change.
The DCO% as a validity measure is complementary to verifica-
tion of diagnosis (Parkin and Muir, 1992). Previously reported
inconsistencies in the DCO complicate the interpretation of inter-
national comparisons ofincidence (Parkin et al, 1994) and survival
(Berrino et al, 1995). Differences between UK regions probably
also result from variable traceback procedures. The significant
district variation found in MCCR is, however, likely to be attribut-
able to differences in otherfactors, such as demography, incidence,
clinical management and survival between population subgroups
and clearly needs further work.
Intemational DCO% are published in 'Cancer Incidence in Five
Continents' (Parkin and Muir, 1992), although they were omitted
for MCCR recently (1983-87 data) precluding accurate compar-
ison. DCO% appear in some, but not all, registry reports and are
generally lower than in MCCR but show similar variation by site
(Black et al, 1993; Thames CancerRegistry, 1995), district (Centre
for Cancer Epidemiology, 1992) and age (Parkin and Muir, 1992).
The shorter time interval (8 months) for successful traceback
between the end of the study period and the creation of the study
dataset partly explains the high overall DCO%, contrasting with
intervals of over 3 years elsewhere (Centre for Cancer
Epidemiology, 1992; Parkin and Muir, 1992; Black et al, 1993;
Thames Cancer Registry, 1995).
Inconsistencies in the DCO% should be resolved by stricter
definition. Conceptually, the DCO is a registration in which 'no
information other than the death certificate is available' (Jensen et
al, 1991). Availability is relative and time dependent - whether
additional information can be found varies with registry effort and
resources. Pragmatically, the definition 'DCO' could apply to a
record containing only DC information, for example 24 months
after death, making the DCO% the proportion ofrecords in which
'only death certificate information is held at 24 months afterdeath,
despite specified search by the registry'.
Improbable or impossible dates are rarely revealed in registry
reports. In MCCR, 2% of records were apparently registered
before their diagnosis. Local discussion suggests that this arises
when dates are imputed by computer software when information is
missing, and through keyboard errors.
CONCLUSION
Although the importance of high-quality cancer registration has
been highlighted (Day and Davies, 1996), the means of achieve-
ment seems less clear. Accurate cancer registry information is
essential for the definition, development and monitoring ofCancer
Units and Centres (Department of Health, 1994), and quality now
forms part ofthe national core contract (NHS Executive, 1996) for
cancer registries. While attempting to put quality assurance into
practice at local level, this study has demonstrated shortcomings
in the scope, definition and use of existing quality assurance
measures, and the absence of explicit standards. Suggestions are
made about clarifying terminology, standardizing existing defini-
tions and adding new measures. Without this, national and inter-
national data comparisons are impoverished, variations can be
ignored as artefactual and data do not improve, ultimately casting
doubt on their use. The measures used here could, with further
development, form the basis of national quality assurance, along-
side the much needed standardization of registry procedutes.
Custom and practice must now give way to a systematic and stan-
dardized approach to quality assurance in cancer registries.
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1. Robles' two-source calculation
n, = number ascertained by source 1
n2= number ascertained by source 2
t= total ascertained from sources 1 and 2 combined
c = overlap (n1 +n2- t)




Variance ofN= varN = n xn2(t-n,) (t- n2)
Using s.e. = lvar, the 95% confidence limits for the estimate
ofascertainment are:
(Nl~~ N t )and( t
tN+ 1.964varN N N- 1.964varN
Example: All sites, Mersey Regional Cancer Registry
(MRCR), 1990-91:
n, = 16379 (source pathology) n2 = 12734 (source death)
t = 24681 c = 4432
Therefore N= 16379 x 12734 = 47060 and t = 24681 = 52.4%
4432 N 47060
varN= 16379 x 12734(24681 - 16379)(24681 - 12734) = 237626
44323
Confidence limits are
( 24681 and ( 24681
47060 + 1.964237626J 47060- 1.964237626J
Estimated ascertainment is thus 52.45% (51.4-53.5%).
2. Modified two-source estimation used for MRCR
Use T = total cases ascertained from all sources available to
registry and calculate estimated ascertainment as T
N
Now T= 27 942 for all cases in MRCR 1990-91
Therefore, estimated ascertainment forall sites = 27942 = 59.4%
47060
And its confidence limits are
6 +27942 1 and4 279426
(47060 + 1.96 )237626 47060- 1.96 4237626
Estimated ascertainment is thus 59.4% (57.2-60.6%).
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